The US cancer society has lowered the recommended age for bowl cancer screening from 50 to 45. This could benefit RHY in the future with their US GTM strategy.
https://unauthorised investment adv...s-as-us-experts-call-for-younger-testing/amp/
A good summary of the RHY opportunity I found on Twitter "One thing $RHY has going for it is that it has a very low market cap ($19 million, $11m EV), compared to $9,6 billion for Exact Sciences, maker of a faecal colon cancer test. Therefore, if performance is maintained in larger prospective trials, the potential is very material"
DEALROOM
New Feature Announcement!
We’re excited to introduce the DealRoom portal, now live on site, providing users with exciting access to private equity opportunities for both pre-IPO and publicly listed companies.
See full details by selecting the new menu item named 'DealRoom' on our main menu bar or click below.
Stay ahead of the market, with HotCopper.